Inovio Pharmaceuticals (($INO)) has held its Q2 earnings call. Read on for the main highlights of the call. Inovio Pharmaceuticals’ recent ...

Inovio Pharmaceuticals Inc. closed 64.40% below its 52-week high of $7.22, which the company reached on September 3rd.

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.

The stock's fall snapped a five-day winning streak.

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. Special ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio third quarter 2024 financial results conference call. At this time, all lines are in a listen-only mode. Following the presentation, we ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

PLYMOUTH MEETING, Pa. (AP) — PLYMOUTH MEETING, Pa. (AP) — Inovio Pharmaceuticals Inc. (INO) on Tuesday reported a loss of $23.5 million in its second quarter. The Plymouth Meeting ...

Inovio Pharmaceuticals ( (INO)) has released its Q3 earnings. Here is a breakdown of the information Inovio Pharmaceuticals presented to its investors. Inovio Pharmaceuticals is a biotechnology ...

Inovio Pharmaceuticals shares are trading higher by 17.9% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses. The next correction is closer than you think.

Lead asset, VGX-3100, is targeting the huge unmet demand in the cervical cancer market. Inovio Pharmaceuticals is focused on rapidly advancing the VGX-3100 research program. There are multiple ...